Navigation Links
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Date:2/5/2009

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA).

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse range of solid tumors. Safety and tolerability data from this study augments data obtained in the company's first Phase I study where CYT997 was administered intravenously. Together, these studies suggest that the CYT997 is a potent and selective VDA which is well tolerated at biologically efficacious doses and is worthy of further investigation as a novel anticancer agent.

"Cytopia has now demonstrated the broad clinical potential of CYT997 in both intravenous and oral forms," said Mr. Andrew Macdonald, CEO. "The oral activity of CYT997 is a key advantage over most other vascular disrupting agents which are administered intravenously. The oral activity of the agent should markedly improve its clinical and commercial value."

The company has already commenced Phase II studies for the intravenous form of CYT997 and intends to undertake similar efficacy studies for the oral presentation. Investigating the safety and efficacy of metronomic dosing, frequent oral administration at a comparatively low, but biologically effective dose, is of particular interest.

This oral trial was partly funded under the company's $A3 million Commercial Ready grant.

Preliminary trial data

CYT997 was generally well tolerated in this study with a maximum tolerated dose in cancer patients of ca 165 mg/m2. This dose resulted in maximal plasma concentrations some twofold higher than those obse
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytopia Scientific Presentations on JAK2 Inhibitor Program
2. Cytopia Commences Second Phase II Study in Brain Cancer
3. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
4. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
5. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
6. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
7. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
8. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
11. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 19, 2014  Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, animal ... invested in Iwase Dental Supply, Inc., a leading full-service ... transaction marks Henry Schein,s entrance into Japan ... market, and increases to 28 the number of countries ...
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... to report its results of operations for the quarter ... after the market closes.  A conference call to discuss ... ET, on Friday, November 7, 2014. Those wishing to ... until Friday, November 14, 2014 by dialing 1-855-859-2056 and ...
(Date:10/17/2014)... 17, 2014 According ... by Technique (Optical Coherence Tomography, Hyperspectral Imaging, ... (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts ... the Optical Imaging market over the forecast ... at $917.1 million in 2014 and is ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
... 2012 Mylan Pharmaceuticals ULC, the Canadian subsidiary ... today received approval from Health Canada for Mylan-Rosuvastatin ... is the generic version of Astra Zeneca,s Crestor® ... primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.  According ...
... GROVE, Ill., March 15, 2012 For the ... (nail fungus), a new, fast, effective approach to ... leader in laser, light, radiofrequency and ultrasound aesthetic ... introduction of its newest innovation for the Harmony(XL) ...
Cached Medicine Technology:Mylan Canada Receives Health Canada Approval for Generic Version of Crestor® 2New Nail Fungus Approach Receives FDA Clearance 2
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... 20, 2014 JZ Fitness, an independently ... corporate wellness programming, authorship, international lecturing and community wellness, ... announce the release of the JZ Fitness nutrition app, ... of coaching thousands of individuals on nutrition, Jenn Zerling ... does not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2
... BioInformatics, LLC announces the pending release of its newest ... Products. As a result of the March 9, ... human embryonic stem cell research, suppliers of stem cell related ... new opportunities in the stem cell products market. In this ...
... Cookbook Hits Shelves April 28, 2009 ... in Twenty Episode, Half-Hour Series from Tiger Aspect Productions ... April 7 Do you want to have your cake ... Yourself Thin , an all-new series that offers viewers the ...
... responds to the publication of a long-secret report by International Committee ... in interrogations in CIA secret detention centers committed gross violations of ... ... Cambridge, MA (Vocus) April 7, 2009 -- The full ...
... Scope of Regulatory Practice, International StandardsROCKVILLE, Md., April ... Society (RAPS) has announced its newest Regulatory Affairs ... RAC (GS) credential denotes knowledge related to the ... the healthcare product sector, regardless of geographic location ...
... April 7 , ... Product Suite , Elsevier, ... information products and services, announced today the acquisition ... the provider of,Softwarefornurses.com online learning education products. PDS ...
... arthritis affects about 11 percent of patients with ... block signaling molecules that induce inflammation, improve the ... human monoclonal antibody that works against TNFα and ... weeks of the first subcutaneous injection in a ...
Cached Medicine News:Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 2Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 2Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 4Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3Health News:RAPS Offers New International Regulatory Affairs Certification - RAC (GS) 2Health News:Elsevier Acquires Professional Development Software, Inc., Provider of 'Software for Nurses' Online Learning Education 2Health News:New drug shows promising results for psoriatic arthritis 2
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
ABS2000 is an automated system that can handle more workload. It allows accurate detection of antibodies that can be missed out by manual testing....
... vision and disposable lens convenience for those ... and want crisp, clear vision with the ... Toric. Vertex Toric lenses are manufactured using ... produces a perfect edge on every lens. ...
Medicine Products: